Is Heron Therapeutics, Inc. overvalued or undervalued?

As of 23 February 2017, the valuation grade for Heron Therapeutics, Inc. has moved from does not qualify to risky. The company is currently considered overvalued based on its financial metrics. Key ratios include a price to book value of -11.26, an EV to EBIT of -124.99, and an EV to EBITDA of -365.76, all indicating significant financial distress and inefficiency.
In comparison to its peers, Heron Therapeutics has a P/E ratio of -38.21, while Stoke Therapeutics, Inc. is rated attractive with a P/E of 12.66, highlighting a stark contrast in valuation. Additionally, Harpoon Therapeutics, Inc. is also classified as risky with a P/E of -28.51, further emphasizing the challenges faced by Heron in its sector. The company's recent stock performance shows a year-to-date return of 37.91%, which is significantly better than the S&P 500's 2.44%, but this does not mitigate the overall valuation concerns.